Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
Spotlight - The Future of Cryopreserved Amniotic Membrane in Oculoplastic Surgery
Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board
Home > Dry Eye > Berberine and niclosamide show promise in treating Demodex blepharitis
  • Dry Eye

Berberine and niclosamide show promise in treating Demodex blepharitis

Kelsey Moroz

A study has demonstrated that water-soluble berberine and lipid-soluble niclosamide effectively inhibit the survival of Demodex folliculorum, a mite associated with ocular conditions like Demodex blepharitis.

Researchers tested various solvents and cosolvents to determine optimal drug formulations. Double-distilled water (DDW) was selected for berberine, while polyethylene glycol 300 (PEG300) was preferred for niclosamide to minimize irritation. The study found that 0.2% berberine significantly reduced Demodex survival compared to the control group (P < 0.001). Niclosamide, at a 0.5% concentration, exhibited a stronger anti-Demodex effect than 20% tea tree oil (P < 0.001).

Niclosamide-treated mites also showed morphological changes, such as increased transparency and body distortion. Both drugs demonstrated good tolerability and safety in a mouse model.

Reference
Guo S, Wang Y, Li J, et al. In vitro killing effect of berberine and niclosamide on ocular Demodex folliculorum. Cont Lens Anterior Eye. 2025;48(2):102336. doi: 10.1016/j.clae.2024.102336. Epub 2024 Nov 30. PMID: 39616005.

Share

Related Content

  • Dry Eye

Analysis of FDA reports reveals widespread ocular adverse events linked to antidepressants

  • Cataract

Optimizing cataract surgery outcomes through dry eye management

  • Dry Eye

Preservative-free lubricants linked to improved dry eye symptoms in real-world study

  • Dry Eye

Spotlight on LACRIFILL®

  • Conference Roundup

If your patient has recurrent chalazia, consider co-occurring Demodex blepharitis

  • Conference Roundup

Ocular staining and dry mouth may help identify Sjögren’s-related dry eye

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Optometry360 Logo

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon